Use of Collagen X Biomarker as a Predictor for Response to Growth Hormone Therapy
Authors' conclusion
Our study confirms prior findings of CXM correlating with baseline AHV. However, that correlation was not significant during the 1 year of GH therapy. This is possibly due to multiple cofounders including differences in GH dosing, underlying diagnoses, and inability to confirm universal adherence to therapy, with some subjects having prolonged pauses in therapy for different reasons. Short-term change in CXM did not accurately predict growth response. Future prospective studies of a larger scale would be needed to investigate the role of CXM as a surrogate for GH therapy response.
Study context
- Population
- Growth hormone (GH)-naïve patients >3 years old about to start GH therapy (any formulation, any indication); mean age 9.12 years, height Z score −2.289 females
- Participants
- 28 patients
- Outcome
- Whether short-term change in CXM at 4 weeks after GH start predicts first-year growth response (change in AHV)
- Follow-up
- 52 weeks
Main finding
As reported in the abstract
Change in CXM baseline to 4 weeks: slope (95% CI −0.168 - 0.201), p = 0.86
0.017
Change in CXM baseline to 52 weeks: slope ((−0.081 - 0.148)), p = 0.57
0.03
Observational data: associations, not effects.
Further findings
Baseline CXM vs baseline annualized height velocity (AHV)
- Slope
- 0.117 (95% CI 0.044-0.019; p = 0.002)
CXM at 52 weeks vs treatment AHV
- Slope (95% CI (−0.046 - 0.094); p = 0.52)
- 0.024
AHV, baseline to after treatment
cm/y
- AHV baseline
- 4.85
- AHV after treatment
- 8.69
CXM, baseline to 52 weeks
ng/mL
- CXM baseline
- 19.11
- CXM at 52 weeks
- 25.04
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →